Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00473577 | Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients | PHASE1 | COMPLETED | 40 | — | — | Aug 1, 2005 | Dec 1, 2007 | Aug 25, 2010 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| CRA-24781 | DRUG | - |
Inclusion Criteria: * age ≥ 18 years * histologically confirmed solid or hematologic malignancy that is refractory to standard therapy or for which no standard therapy exists * estimated life expectancy \> 12 weeks * ECOG performance grade ≤ 2 * creatinine ≤ 1.5 X institutional upper limit of norma...